Mode
Text Size
Log in / Sign up
Phase 2 N=21 Randomized Triple-blind Treatment

Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals

Marijuana Abuse

Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Oct 2014
Primary outcome: Primary: Marijuana Use — 2.5; 3.9 Reported uses per day

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
citicoline (Drug); placebo (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Mclean Hospital
Primary completion
Jan 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Marijuana Use
2.5; 3.9
SECONDARY
Neurocognitive Function
32.45; 16.08

Summary

The Three Aims of this study are (only studies for Aim 1 were completed) 1. Measure the impact of citicoline on marihuana use patterns in subjects' individualized natural settings and responses to marihuana challenge using functional brain MRI scans. Hypothesis - 2 g/day citicoline will produce greater reductions in marihuana use and craving in heavy marihuana users than placebo citicoline over a 8-week treatment period as measured in their natural environments. The same participants will experience greater improved brain activation patterns and an improvement in cognitive functioning compared to placebo controlled subjects. 2. Measure the effects of citicoline on marihuana absorption and metabolism and determine if these changes parallel changes in subjective and physiological responses in a laboratory setting. Hypothesis - Chronic (8 weeks) treatment with 2 g/day citicoline will produce increases in subjective and physiological effects of both acute marihuana smoking and placebo marihuana smoking compared to chronic placebo citicoline. Citicoline will have no effect on marihuana pharmacokinetics. 3. Measure the effects of citicoline on marijuana-induced cue-induced craving and brain electrical activity (EEG). Hypothesis - Chronic (8 weeks) treatment with 2 g/day citicoline will reduce objective measures of marijuana cue-reactivity, and subjective reports of craving in response to marihuana cues will also be attenuated compared to chronic placebo citicoline treatment.

Eligibility Criteria

Inclusion Criteria

  • Meets DSM-IV criteria for current marijuana dependence
  • Women with a negative pregnancy test prior to study entry
  • Heavy smoker, defined as smoking more than 10 joints per week

Exclusion Criteria

  • Abnormal electrocardiogram (ECG)
  • Medical disorder that requires prescription medication
  • Psychiatric disorder that requires prescription medication
  • Abnormal liver function tests
  • Taking herbal preparations
  • Taking any over-the-counter medications on a chronic basis
  • Pregnancy or breast feeding
  • Neurological, infectious, or neoplastic disease
  • Currently seeking treatment for marijuana abuse
  • Meets criteria for alcohol, cocaine, or opioid dependence
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00158249). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search